Galderma's Nemolizumab Shows Clinical Improvement in Itch, Sleep Disturbance

03:14 AM EST, 12/17/2025 (MT Newswires) -- Galderma Group (GALD.SW) said Wednesday that nemolizumab exhibited rapid action on itch and sleep in patients with atopic dermatitis and prurigo nodularis. New data from a post-hoc analysis of the phase 3 Arcadia and Olympia clinical trials confirmed that nemolizumab showed significant improvements as early as 48 hours after treatment. The Swiss dermatology company said nemolizumab reduced itch and improved sleep disturbance within two days. Significant and clinically meaningful responses were observed by day 14 in a quarter of patients with atopic dermatitis and more than a third of patients with prurigo nodularis.